默克表示，接获AstraZeneca(AZN)通知，指出AstraZeneca执行其选择权，今年将购入默克持有的非质子帮浦抑制剂产品股权，这些产品包括Atacand,LEXxel,Plendil,Entocort,特定目前临床开发产品。四月份默克将收取6.47亿美元款项。(Bioon.com)
推荐延伸阅读
默克（Merck）以72亿美元收购密理博（Millipore）
阿斯利康（AstraZeneca）欲将其原料药生产外包给亚洲厂商
阿斯利康即将再度裁减销售人员
推荐新闻
Astra unties part of U.S. Merck deal for $647 million
LONDON (Reuters) - AstraZeneca said Monday it was exercising an option with Merck & Co to take back full rights to certain drugs marketed in the United States and would pay the U.S. group $647 million in April.
The payout, which had been anticipated by investors, is part of the staged unwinding of a complex relationship between the companies that entitles Merck to a royalty on U.S. sales of many AstraZeneca medicines.
Products covered by the option include Entocort for Crohn's disease, the heart drugs Atacand and Plendil, and certain products still in development, including AstraZeneca's potential blockbuster blood-thinner Brilinta.
The appraised value of $647 million was first set out in 2008.
AstraZeneca also has a second option to repurchase Merck's interest in its top-selling heartburn drug Nexium and the older product Prilosec. That option is exercisable in 2012, or 2017, or if combined annual sales of the two products fall below a minimum amount.
The agreement with Merck dates back to a 1982 selling and distribution joint venture originally set up with Sweden's Astra, which was restructured in 1998.
The British-based group has long argued that ending the alliance with Merck makes good business sense since it will relieve it from costly contingent payments and increase its freedom to operate.
AstraZeneca shares were 1.6 percent higher at 1320 GMT, outperforming a 0.6 percent gain in the STOXX Europe Healthcare index.
